Y-MABS THERAPEUTICS INC. - COMMON STOCK

Y-mAbs to Announce Third Quarter 2022 Financial and Operating Results on November 7, 2022

02 11 2022 15:01:00 提供 Nasdaq GlobeNewswire

Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab

28 10 2022 14:33:33 提供 Nasdaq GlobeNewswire

Y-mAbs Announces Pivotal Data for Omburtamab

03 10 2022 08:00:01 提供 Nasdaq GlobeNewswire

Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

26 9 2022 08:00:00 提供 Nasdaq GlobeNewswire

Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab

01 9 2022 15:05:00 提供 Nasdaq GlobeNewswire

Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma

30 8 2022 08:00:01 提供 Nasdaq GlobeNewswire

Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments

08 8 2022 15:05:02 提供 Nasdaq GlobeNewswire

Y-mAbs to Announce Second Quarter 2022 Financial and Operating Results on August 8, 2022

02 8 2022 08:00:00 提供 Nasdaq GlobeNewswire

Y-mAbs’ Announces Clearance of IND for GD2-SADA

12 7 2022 08:00:02 提供 Nasdaq GlobeNewswire

Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS® (omburtamab) for the Treatment of Neuroblastoma for Priority Review

31 5 2022 08:00:01 提供 Nasdaq GlobeNewswire

Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint

26 5 2022 15:01:00 提供 Nasdaq GlobeNewswire

Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments

09 5 2022 15:01:00 提供 Nasdaq GlobeNewswire

Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022

03 5 2022 15:01:00 提供 Nasdaq GlobeNewswire

Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Financial Update

27 4 2022 15:01:00 提供 Nasdaq GlobeNewswire

Y-mAbs Announces Presentation of SADA Technology at AACR

08 4 2022 08:00:00 提供 Nasdaq GlobeNewswire

Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA

01 4 2022 08:00:00 提供 Nasdaq GlobeNewswire

Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments

24 2 2022 15:01:01 提供 Nasdaq GlobeNewswire

Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022

17 2 2022 08:00:01 提供 Nasdaq GlobeNewswire

Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab

11 2 2022 08:00:00 提供 Nasdaq GlobeNewswire

Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

05 1 2022 08:00:01 提供 Nasdaq GlobeNewswire